175 related articles for article (PubMed ID: 34394349)
1. Real-World Efficacy and Safety of Bevacizumab in the First-Line Treatment of Metastatic Cervical Cancer: A Cohort Study in the Total Population of Croatian Patients.
Čerina D; Matković V; Katić K; Belac Lovasić I; Šeparović R; Canjko I; Jakšić B; Petrić-Miše B; Bajić Ž; Boban M; Vrdoljak E
J Oncol; 2021; 2021():2815623. PubMed ID: 34394349
[TBL] [Abstract][Full Text] [Related]
2. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
Tappenden P; Jones R; Paisley S; Carroll C
Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin plus paclitaxel chemotherapy with or without bevacizumab in postmenopausal women with previously untreated advanced cervical cancer: a retrospective study.
Chu G; Liu X; Yu W; Chen M; Dong L
BMC Cancer; 2021 Feb; 21(1):133. PubMed ID: 33549065
[TBL] [Abstract][Full Text] [Related]
4. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
Wagner AD; Thomssen C; Haerting J; Unverzagt S
Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin-based chemotherapy with or without bevacizumab for Chinese postmenopausal women with advanced cervical cancer: a retrospective observational study.
He X; Liu J; Xiao L; Zhao M; Su T; Liu T; Han G; Wang Y
BMC Cancer; 2020 May; 20(1):381. PubMed ID: 32370739
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of bevacizumab in Turkish patients with metastatic and recurrent cervical cancer.
Ercelep Ö; Tataroğlu D; Özçelik M; Sürmeli H; Değirmenci M; İnanç M; Aliustaoğlu M; Gümüş M
Turk J Obstet Gynecol; 2020 Jun; 17(2):123-127. PubMed ID: 32850187
[TBL] [Abstract][Full Text] [Related]
7. Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: A Real-World Study from China.
Peng W; Zhang F; Wang Z; Li D; He Y; Ning Z; Sheng L; Wang J; Xia X; Yu C; Wang Z; Zhao Y; Liang H; Hu B; Sun C; Wang D; Cheng Y; Pan M; Xia L; Guo X; Zhang Y; Hu Z; Li X; Lu L; Zhang J; Qian H; Xie H; Sun G
Cancer Manag Res; 2020; 12():6977-6985. PubMed ID: 32821164
[TBL] [Abstract][Full Text] [Related]
8. Impact of Primary Tumor Location on First-line Bevacizumab or Cetuximab in Metastatic Colorectal Cancer.
Snyder M; Bottiglieri S; Almhanna K
Rev Recent Clin Trials; 2018; 13(2):139-149. PubMed ID: 29595113
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study.
Delaloge S; Pérol D; Courtinard C; Brain E; Asselain B; Bachelot T; Debled M; Dieras V; Campone M; Levy C; Jacot W; Lorgis V; Veyret C; Dalenc F; Ferrero JM; Uwer L; Kerbrat P; Goncalves A; Mouret-Reynier MA; Petit T; Jouannaud C; Vanlemmens L; Chenuc G; Guesmia T; Robain M; Cailliot C
Ann Oncol; 2016 Sep; 27(9):1725-32. PubMed ID: 27436849
[TBL] [Abstract][Full Text] [Related]
10. Real-World Efficacy of Bevacizumab in Patients With Recurrent Epithelial Ovarian Cancer.
Hung JN; Hsu ST; Sun L; Hwang SF; Liu CK; Shih YH; Chen MJ; Wang JS; Lu CH
Front Oncol; 2022; 12():843278. PubMed ID: 35664738
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in "real world" patients.
Godoy-Ortiz A; Plata Y; Alcaide J; Galeote A; Pajares B; Saez E; Alba E; Sánchez-Muñoz A
Clin Transl Oncol; 2018 Jul; 20(7):922-927. PubMed ID: 29222647
[TBL] [Abstract][Full Text] [Related]
12. Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT).
Bennouna J; Phelip JM; André T; Asselain B; Sébastien Koné ; Ducreux M
Clin Colorectal Cancer; 2017 Jun; 16(2):129-140.e4. PubMed ID: 28277294
[TBL] [Abstract][Full Text] [Related]
13. The 'real-life' impact of adding bevacizumab to first-line therapy in metastatic colorectal cancer patients: a large Israeli retrospective cohort study.
Hammerman A; Greenberg-Dotan S; Battat E; Feldhamer I; Bitterman H; Brenner B
Acta Oncol; 2015 Feb; 54(2):164-70. PubMed ID: 25350524
[TBL] [Abstract][Full Text] [Related]
14. Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041).
Lee JY; Park JY; Park SY; Lee JW; Kim JW; Kim YB; Jeong DH; Lee KB; Kim TH; Lee IH; Choi MC; Kim KH; Kim YM; Lee YJ; Kang S; ; Pujade-Lauraine E
Gynecol Oncol; 2019 Jan; 152(1):61-67. PubMed ID: 30409490
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of bevacizumab in addition to platinum-based chemotherapy for the first-line treatment of patients with advanced nonsquamous non-small-cell lung cancer: Final results of AVALANCHE, an observational cohort study.
Tolnay E; Ghimessy ÁK; Juhász E; Sztancsik Z; Losonczy G; Dombi P; Vennes Z; Helf L; Csada E; Sárosi V
Oncol Lett; 2019 Feb; 17(2):1750-1760. PubMed ID: 30675234
[TBL] [Abstract][Full Text] [Related]
16. Real world study of regimen containing bevacizumab as first-line therapy in Chinese patients with advanced non-small cell lung cancer.
Xing P; Mu Y; Wang Y; Hao X; Zhu Y; Hu X; Wang H; Liu P; Lin L; Wang Z; Li J
Thorac Cancer; 2018 Jul; 9(7):805-813. PubMed ID: 29768721
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.
Sun L; Ma JT; Zhang SL; Zou HW; Han CB
Med Oncol; 2015 Feb; 32(2):473. PubMed ID: 25603953
[TBL] [Abstract][Full Text] [Related]
18. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.
Brufsky AM; Hurvitz S; Perez E; Swamy R; Valero V; O'Neill V; Rugo HS
J Clin Oncol; 2011 Nov; 29(32):4286-93. PubMed ID: 21990397
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Bevacizumab Combined With First-Line Chemotherapy in Elderly (≥75 Years) Patients With Metastatic Colorectal Cancer: A Real-World Study.
François E; Mineur L; Deplanque G; Laplaige P; Smith D; Gourgou S; Tanang A; Ionescu-Goga M; Veerabudun K; Lelarge Y; Kim S; Rollot F
Clin Colorectal Cancer; 2020 Sep; 19(3):e100-e109. PubMed ID: 32299778
[TBL] [Abstract][Full Text] [Related]
20. Triplet chemotherapy vs doublet chemotherapy plus bevacizumab in metastatic, recurrent, and persistent cervical cancer.
Choi HJ; Lee YY; Choi CH; Kim TJ; Lee JW; Bae JH; Bae DS; Kim BG
Curr Probl Cancer; 2020 Oct; 44(5):100557. PubMed ID: 32067746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
